MedTrace Logo

Exploratory Study of DHA in Systemic Lupus Erythematosus Patients

NCT03396393 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2018-01-23

No results posted yet for this study

Summary

The primary objective of the study is to assess the efficacy of DHA in patients with SLE.

Conditions

Interventions

DRUG

Dihydroartemisinin tablet

DHA tablet

DRUG

Placebo tablet

Placebo tablet

Sponsors & Collaborators

  • Kunming Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Fengchun Zhang, Prof. · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-31
Primary Completion
2021-12-31
Completion
2022-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03396393 on ClinicalTrials.gov